Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

10.1016/j.jacc.2021.04.079

Saved in:
Bibliographic Details
Main Authors: Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators.
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Article
Published: Elsevier Inc. 2022
Subjects:
chronic kidney disease
clinical trial
finerenone
mineralocorticoid receptor antagonist
new-onset atrial fibrillation
type 2 diabetes
Online Access:https://scholarbank.nus.edu.sg/handle/10635/232604
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

https://scholarbank.nus.edu.sg/handle/10635/232604

Similar Items